Expression of activated integrin β7 in multiple myeloma patients

Naoki Hosen; Satoshi Yoshihara; Hiroyuki Takamatsu; Masaki Ri; Yasuyuki Nagata; Hiroshi Kosugi; Yoshimitsu Shimomura; Ichiro Hanamura; Shigeo Fuji; Koichiro Minauchi; Junya Kuroda; Rikio Suzuki; Noriko Nishimura; Nobuhiko Uoshima; Hirohisa Nakamae; Yawara Kawano; Ishikazu Mizuno; Hiroshi Gomyo; Kenshi Suzuki; Shuji Ozaki; Shingen Nakamura; Yoichi Imai; Masahiro Kizaki; Eiju Negoro; Hiroshi Handa; Shinsuke Iida

doi:10.1007/s12185-021-03162-2

Expression of activated integrin β7 in multiple myeloma patients

Naoki Hosen
, Satoshi Yoshihara
, Hiroyuki Takamatsu
, Masaki Ri
, Yasuyuki Nagata
, Hiroshi Kosugi
, Yoshimitsu Shimomura
, Ichiro Hanamura
, Shigeo Fuji
, Koichiro Minauchi
, Junya Kuroda
, Rikio Suzuki
, Noriko Nishimura
, Nobuhiko Uoshima
, Hirohisa Nakamae
, Yawara Kawano
, Ishikazu Mizuno
, Hiroshi Gomyo
, Kenshi Suzuki
, Shuji Ozaki

Shingen Nakamura, Yoichi Imai, Masahiro Kizaki, Eiju Negoro, Hiroshi Handa, Shinsuke Iida

Department of Medicine

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Multiple myeloma (MM) is still extremely difficult to cure, and new therapeutic drugs are needed. We recently found that integrin β7 is constitutively activated in MM cells, and chimeric antigen receptor (CAR) T cells targeting activated integrin β7 have a significant anti-MM effect. In this study, we performed flow cytometry analysis of the expression of activated integrin β7 in bone marrow cells from 137 symptomatic MM patients. In 60/137 (44%) MM patients, activated integrin β7 was detected in most MM cells (> 80% of MM cells were in the positive gate). Activated integrin β7 was highly expressed in MM cells even in heavily treated patients. It also showed high expression in many CD38^lo/⁻CD138⁻CD19⁺B cells, which reportedly include clonotypic B cells, in the bone marrow of MM patients. Taken together, these results suggest that CAR T-cell therapy targeting activated integrin β7 has the potential to benefit many patients with relapsed or refractory MM.

Original language	English (US)
Pages (from-to)	3-7
Number of pages	5
Journal	International journal of hematology
Volume	114
Issue number	1
DOIs	https://doi.org/10.1007/s12185-021-03162-2
State	Published - Jul 2021

All Science Journal Classification (ASJC) codes

Hematology

Access to Document

10.1007/s12185-021-03162-2

Cite this

Hosen, N., Yoshihara, S., Takamatsu, H., Ri, M., Nagata, Y., Kosugi, H., Shimomura, Y., Hanamura, I., Fuji, S., Minauchi, K., Kuroda, J., Suzuki, R., Nishimura, N., Uoshima, N., Nakamae, H., Kawano, Y., Mizuno, I., Gomyo, H., Suzuki, K., ... Iida, S. (2021). Expression of activated integrin β7 in multiple myeloma patients. International journal of hematology, 114(1), 3-7. https://doi.org/10.1007/s12185-021-03162-2

@article{023eb1a9773d4f94bddd52732d722738,

title = "Expression of activated integrin β7 in multiple myeloma patients",

abstract = "Multiple myeloma (MM) is still extremely difficult to cure, and new therapeutic drugs are needed. We recently found that integrin β7 is constitutively activated in MM cells, and chimeric antigen receptor (CAR) T cells targeting activated integrin β7 have a significant anti-MM effect. In this study, we performed flow cytometry analysis of the expression of activated integrin β7 in bone marrow cells from 137 symptomatic MM patients. In 60/137 (44\%) MM patients, activated integrin β7 was detected in most MM cells (> 80\% of MM cells were in the positive gate). Activated integrin β7 was highly expressed in MM cells even in heavily treated patients. It also showed high expression in many CD38lo/−CD138−CD19+B cells, which reportedly include clonotypic B cells, in the bone marrow of MM patients. Taken together, these results suggest that CAR T-cell therapy targeting activated integrin β7 has the potential to benefit many patients with relapsed or refractory MM.",

author = "Naoki Hosen and Satoshi Yoshihara and Hiroyuki Takamatsu and Masaki Ri and Yasuyuki Nagata and Hiroshi Kosugi and Yoshimitsu Shimomura and Ichiro Hanamura and Shigeo Fuji and Koichiro Minauchi and Junya Kuroda and Rikio Suzuki and Noriko Nishimura and Nobuhiko Uoshima and Hirohisa Nakamae and Yawara Kawano and Ishikazu Mizuno and Hiroshi Gomyo and Kenshi Suzuki and Shuji Ozaki and Shingen Nakamura and Yoichi Imai and Masahiro Kizaki and Eiju Negoro and Hiroshi Handa and Shinsuke Iida",

note = "Publisher Copyright: {\textcopyright} 2021, Japanese Society of Hematology.",

year = "2021",

month = jul,

doi = "10.1007/s12185-021-03162-2",

language = "English (US)",

volume = "114",

pages = "3--7",

journal = "International journal of hematology",

issn = "0925-5710",

publisher = "Springer",

number = "1",

}

Hosen, N, Yoshihara, S, Takamatsu, H, Ri, M, Nagata, Y, Kosugi, H, Shimomura, Y, Hanamura, I, Fuji, S, Minauchi, K, Kuroda, J, Suzuki, R, Nishimura, N, Uoshima, N, Nakamae, H, Kawano, Y, Mizuno, I, Gomyo, H, Suzuki, K, Ozaki, S, Nakamura, S, Imai, Y, Kizaki, M, Negoro, E, Handa, H & Iida, S 2021, 'Expression of activated integrin β7 in multiple myeloma patients', International journal of hematology, vol. 114, no. 1, pp. 3-7. https://doi.org/10.1007/s12185-021-03162-2

TY - JOUR

T1 - Expression of activated integrin β7 in multiple myeloma patients

AU - Hosen, Naoki

AU - Yoshihara, Satoshi

AU - Takamatsu, Hiroyuki

AU - Ri, Masaki

AU - Nagata, Yasuyuki

AU - Kosugi, Hiroshi

AU - Shimomura, Yoshimitsu

AU - Hanamura, Ichiro

AU - Fuji, Shigeo

AU - Minauchi, Koichiro

AU - Kuroda, Junya

AU - Suzuki, Rikio

AU - Nishimura, Noriko

AU - Uoshima, Nobuhiko

AU - Nakamae, Hirohisa

AU - Kawano, Yawara

AU - Mizuno, Ishikazu

AU - Gomyo, Hiroshi

AU - Suzuki, Kenshi

AU - Ozaki, Shuji

AU - Nakamura, Shingen

AU - Imai, Yoichi

AU - Kizaki, Masahiro

AU - Negoro, Eiju

AU - Handa, Hiroshi

AU - Iida, Shinsuke

PY - 2021/7

Y1 - 2021/7

N2 - Multiple myeloma (MM) is still extremely difficult to cure, and new therapeutic drugs are needed. We recently found that integrin β7 is constitutively activated in MM cells, and chimeric antigen receptor (CAR) T cells targeting activated integrin β7 have a significant anti-MM effect. In this study, we performed flow cytometry analysis of the expression of activated integrin β7 in bone marrow cells from 137 symptomatic MM patients. In 60/137 (44%) MM patients, activated integrin β7 was detected in most MM cells (> 80% of MM cells were in the positive gate). Activated integrin β7 was highly expressed in MM cells even in heavily treated patients. It also showed high expression in many CD38lo/−CD138−CD19+B cells, which reportedly include clonotypic B cells, in the bone marrow of MM patients. Taken together, these results suggest that CAR T-cell therapy targeting activated integrin β7 has the potential to benefit many patients with relapsed or refractory MM.

AB - Multiple myeloma (MM) is still extremely difficult to cure, and new therapeutic drugs are needed. We recently found that integrin β7 is constitutively activated in MM cells, and chimeric antigen receptor (CAR) T cells targeting activated integrin β7 have a significant anti-MM effect. In this study, we performed flow cytometry analysis of the expression of activated integrin β7 in bone marrow cells from 137 symptomatic MM patients. In 60/137 (44%) MM patients, activated integrin β7 was detected in most MM cells (> 80% of MM cells were in the positive gate). Activated integrin β7 was highly expressed in MM cells even in heavily treated patients. It also showed high expression in many CD38lo/−CD138−CD19+B cells, which reportedly include clonotypic B cells, in the bone marrow of MM patients. Taken together, these results suggest that CAR T-cell therapy targeting activated integrin β7 has the potential to benefit many patients with relapsed or refractory MM.

UR - https://www.scopus.com/pages/publications/85105991837

UR - https://www.scopus.com/pages/publications/85105991837#tab=citedBy

U2 - 10.1007/s12185-021-03162-2

DO - 10.1007/s12185-021-03162-2

M3 - Article

C2 - 33999338

AN - SCOPUS:85105991837

SN - 0925-5710

VL - 114

SP - 3

EP - 7

JO - International journal of hematology

JF - International journal of hematology

IS - 1

ER -

Expression of activated integrin β7 in multiple myeloma patients

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this